Nicotinic acetylcholine receptors as targets in inflammatory and neurodegenerative processes

烟碱乙酰胆碱受体作为炎症和神经退行性过程的靶标

• 批准号: DP0986281
• 负责人: Prof Norelle Daly
• 金额: $ 14.54万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2009
• 资助国家: 澳大利亚
• 起止时间: 2009-01-01 至 2011-12-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0986281
• 关键词: Nicotinic; acetylcholine; receptors; targets; inflammatory

The national/community benefits that are expected to arise from this research are economic and social in nature. The novel approach employed in this project to identify inflammatory pathways and regulation has the potential to provide information that is critical in the design of novel peptide/protein based drugs. With blockbuster protein-based drugs having sales in excess of $10 billion per annum this proposal has the potential for very significant economic benefits for Australia. Furthermore, novel therapeutic agents for inflammatory diseases would have social benefits for Australia by decreasing the number of individuals affected and thereby reducing the physical and emotional stress associated with inflammatory diseases.

这项研究预期带来的国家/社区效益本质上是经济和社会效益。该项目中采用的识别炎症途径和调节的新方法有可能提供在新型肽/蛋白质药物设计中至关重要的信息。由于重磅蛋白质药物的年销售额超过 100 亿美元，该提案有可能为澳大利亚带来非常显着的经济效益。此外，用于炎症性疾病的新型治疗剂可以减少受影响的人数，从而减少与炎症性疾病相关的身体和情绪压力，从而为澳大利亚带来社会效益。